Recombinant Human Tyro3/Dtk Protein

COA

级别和纯度:

≥95%(SDS-PAGE)

表达系统: HEK293
Accession #: Q06418
蛋白标签: C-hFc & His
生物活性: Immobilized Human Gas6 at 2 μg/mL (100 μL/well) can bind Human TYRO3 with a linear range of 0.1-5.6 ng/mL.
内毒素水平: <0.1 EU/μg

有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭

货号 (SKU)	包装规格	是否现货
rp152849-10μg	10μg	现货
rp152849-50μg	50μg	现货
rp152849-100μg	100μg	现货
rp152849-1mg	1mg	期货

查看相关系列

点击查看蛋白信息: TYRO3

Accession#:Q06418 (2) Dtk (1) Gene ID:7301 (2) TYRO3 (2)

Skip to the end of the images gallery

Skip to the beginning of the images gallery

基本描述

产品名称	Recombinant Human Tyro3/Dtk Protein
别名	重组人酪氨酸蛋白激酶受体3 \| 重组人 Tyro3/Dtk 蛋白
英文别名	Brt \| BYK \| DTK \| Etk-2 \| protein tyrosine kinase 3 \| Rek \| RSE \| SKY \| Tif \| tyro3 \| TYRO3 protein tyrosine kinase \| TYRO3_HUMAN \| Tyrosine-protein kinase byk \| Tyrosine-protein kinase DTK \| Tyrosine-protein kinase receptor TYRO3 \| Tyrosine-protein kinas
规格或纯度	ActiBioPure™, Bioactive, Animal Free, Carrier Free, Azide Free, ≥95%(SDS-PAGE)
产品介绍	Purity ≥95% (SDS-PAGE) Endotoxin level ＜0.1 EU/μg Function May be involved in cell adhesion processes, particularly in the central nervous system. In case of filovirus infection, seems to function as a cell entry factor.
生物活性	Immobilized Human Gas6 at 2 μg/mL (100 μL/well) can bind Human TYRO3 with a linear range of 0.1-5.6 ng/mL.
内毒素水平	<0.1 EU/μg
表达系统	HEK293
种属	人(Human)
氨基酸	41-428 aa
序列	AGLKLMGAPVKLTVSQGQPVKLNCSVEGMEEPDIQWVKDGAVVQNLDQLYIPVSEQHWIGFLSLKSVERSDAGRYWCQVEDGGETEISQPVWLTVEGVPFFTVEPKDLAVPPNAPFQLSCEAVGPPEPVTIVWWRGTTKIGGPAPSPSVLNVTGVTQSTMFSCEAHNLKGLASSRTATVHLQALPAAPFNITVTKLSSSNASVAWMPGADGRALLQSCTVQVTQAPGGWEVLAVVVPVPPFTCLLRDLVPATNYSLRVRCANALGPSPYADWVPFQTKGLAPASAPQNLHAIRTDSGLILEWEEVIPEAPLEGPLGPYKLSWVQDNGTQDELTVEGTRANLTGWDPQKDLIVRVCVSNAVGCGPWSQPLVVSSHDRAGQQGPPHSRTSENLYFQGMDPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKHHHHHH
纯度	≥95% (SDS-PAGE)
蛋白标签	C-hFc & His
无载体	Yes
无动物源	Yes
Accession #	Q06418
来源	重组表达
预测分子量	70 kDa
SDS-PAGE	90-110 kDa, under reducing conditions

储存与运输

物理形态	冻干(Lyophilized)
储存缓冲液	Lyophilized from 10mM PBS, 5% Trehalose, 5% Mannitol, pH 7.4
复溶	Reconstitute in sterile water to a concentration of 0.1-0.5 mg/ml.
储存温度	-20°C储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	在 -20~-80℃ 下可保存 1 年以上。收货后建议分装。避免冷冻/解冻循环。
分子类型	蛋白质

图片

Protein Bioactivity: Recombinant Human Tyro3/Dtk Protein (rp152849)

Recombinant Human Tyro3/Dtk Protein (rp152849) - Protein Bioactivity
Immobilized Human Gas6 at 2.0 μg/mL can bind Recombinant Human Tyro3/Dtk Protein (rp152849) with a linear range of 0.1 - 4.5 ng/mL. The EC₅₀ for this effect is 5.1 ng/mL.

SDS-PAGE: Recombinant Human Tyro3/Dtk Protein (rp152849)

Recombinant Human Tyro3/Dtk Protein (rp152849) - SDS-PAGE
3 μg/lane of Recombinant Human Tyro3/Dtk Protein was resolved with SDS-PAGE under reducing (R) and non-reducing (N) conditions and visualized by Coomassie® Blue staining, showing the band at 90 - 110 kDa under reducing conditions and 90 - 110 & 180 - 220 kDa under non-reducing conditions.

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到6个结果

批号(Lot Number)	证书类型	货号
ZJ24F0707623	分析证书	rp152849
ZJ24F0707624	分析证书	rp152849
ZJ24F0707625	分析证书	rp152849
ZJ24F1215390	分析证书	rp152849
ZJ24F1215391	分析证书	rp152849
ZJ24F1215392	分析证书	rp152849

技术文档和文章

阿拉丁®靶点蛋白

Categories: 技术文章

探索主题:

药物开发信号通路细胞因子靶点蛋白药物靶点受体免疫检查点细胞表面标记物

可替换产品

引用文献

1. Stitt TN, Conn G, Gore M, Lai C, Bruno J, Radziejewski C, Mattsson K, Fisher J, Gies DR, Jones PF. (1995) The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases.. Cell, 80 (4): (661-70). [PMID:7867073]
2. Nagata K, Ohashi K, Nakano T, Arita H, Zong C, Hanafusa H, Mizuno K. (1996) Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases.. J Biol Chem, 271 (47): (30022-7). [PMID:8939948]
3. Heiring C, Dahlbäck B, Muller YA. (2004) Ligand recognition and homophilic interactions in Tyro3: structural insights into the Axl/Tyro3 receptor tyrosine kinase family.. J Biol Chem, 279 (8): (6952-8). [PMID:14623883]
4. Mollard A, Warner SL, Call LT, Wade ML, Bearss JJ, Verma A, Sharma S, Vankayalapati H, Bearss DJ. (2011) Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors.. ACS Med Chem Lett, 2 (12): (907-912). [PMID:22247788]
5. Okuzumi T, Fiedler D, Zhang C, Gray DC, Aizenstein B, Hoffman R, Shokat KM. (2009) Inhibitor hijacking of Akt activation.. Nat Chem Biol, 5 (7): (484-93). [PMID:19465931]
6. Paolino M, Choidas A, Wallner S, Pranjic B, Uribesalgo I, Loeser S, Jamieson AM, Langdon WY, Ikeda F, Fededa JP et al.. (2014) The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells.. Nature, 507 (7493): (508-12). [PMID:24553136]
7. Hobson AD, Harris CM, van der Kam EL, Turner SC, Abibi A, Aguirre AL, Bousquet P, Kebede T, Konopacki DB, Gintant G et al.. (2015) Discovery of A-971432, An Orally Bioavailable Selective Sphingosine-1-Phosphate Receptor 5 (S1P5) Agonist for the Potential Treatment of Neurodegenerative Disorders.. J Med Chem, 58 (23): (9154-70). [PMID:26509640]
8. Weihe Zhang,Dehui Zhang,Michael A Stashko,Deborah DeRyckere,Debra Hunter,Dmitri Kireev,Michael J Miley,Christopher Cummings,Minjung Lee,Jacqueline Norris-Drouin,Wendy M Stewart,Susan Sather,Yingqiu Zhou,Gregory Kirkpatrick,Mischa Machius,William P Janzen,H Shelton Earp,Douglas K Graham,Stephen V Frye,Xiaodong Wang. (2013-11-08) Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors.. Journal of medicinal chemistry, 56 ((23)): (9683-9692). [PMID:24195762]
9. Emily J Hanan,Charles Eigenbrot,Marian C Bryan,Daniel J Burdick,Bryan K Chan,Yuan Chen,Jennafer Dotson,Robert A Heald,Philip S Jackson,Hank La,Michael D Lainchbury,Shiva Malek,Hans E Purkey,Gabriele Schaefer,Stephen Schmidt,Eileen M Seward,Steve Sideris,Christine Tam,Shumei Wang,Siew Kuen Yeap,Ivana Yen,Jianping Yin,Christine Yu,Inna Zilberleyb,Timothy P Heffron. (2014-11-11) Discovery of selective and noncovalent diaminopyrimidine-based inhibitors of epidermal growth factor receptor containing the T790M resistance mutation.. Journal of medicinal chemistry, 57 ((23)): (10176-10191). [PMID:25383627]
10. McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A, Lee D, Rothenberg SM, Supko JG, Sordella R, Ulkus LE, Iafrate AJ, Maheswaran S, Njauw CN, Tsao H, Drew L, Hanke JH, Ma XJ, Erlander MG, Gray NS, Haber DA, Settleman J.. (2007) Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.. Proc Natl Acad Sci U S A, 104 (50): (19936-19941). [PMID:18077425] [10.1073/pnas.0707498104]
11. Liu J, Yang C, Simpson C, Deryckere D, Van Deusen A, Miley MJ, Kireev D, Norris-Drouin J, Sather S, Hunter D, Korboukh VK, Patel HS, Janzen WP, Machius M, Johnson GL, Earp HS, Graham DK, Frye SV, Wang X.. (2012) Discovery of Novel Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia.. ACS Med Chem Lett, 3 (2): (129-134). [PMID:22662287] [10.1021/ml200239k]
12. Lin WH, Hsu JT, Hsieh SY, Chen CT, Song JS, Yen SC, Hsu T, Lu CT, Chen CH, Chou LH, Yang YN, Chiu CH, Chen CP, Tseng YJ, Yen KJ, Yeh CF, Chao YS, Yeh TK, Jiaang WT.. (2013) Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).. Bioorg Med Chem, 21 (11): (2856-2867). [PMID:23618709] [10.1016/j.bmc.2013.03.083]
13. Zhang W, McIver AL, Stashko MA, DeRyckere D, Branchford BR, Hunter D, Kireev D, Miley MJ, Norris-Drouin J, Stewart WM, Lee M, Sather S, Zhou Y, Di Paola JA, Machius M, Janzen WP, Earp HS, Graham DK, Frye SV, Wang X.. (2013) Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis.. J Med Chem, 56 (23): (9693-9700). [PMID:24219778] [10.1021/jm4013888]
14. Zhang W, DeRyckere D, Hunter D, Liu J, Stashko MA, Minson KA, Cummings CT, Lee M, Glaros TG, Newton DL, Sather S, Zhang D, Kireev D, Janzen WP, Earp HS, Graham DK, Frye SV, Wang X.. (2014) UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor.. J Med Chem, 57 (16): (7031-7041). [PMID:25068800] [10.1021/jm500749d]
15. Nakano H, Hasegawa T, Saito N, Furukawa K, Mukaida N, Kojima H, Okabe T, Nagano T.. (2015) Design and synthesis of an in vivo-efficacious PIM3 kinase inhibitor as a candidate anti-pancreatic cancer agent.. Bioorg Med Chem Lett, 25 (24): (5687-5693). [PMID:26547690] [10.1016/j.bmcl.2015.10.098]
16. Daydé-Cazals B, Fauvel B, Singer M, Feneyrolles C, Bestgen B, Gassiot F, Spenlinhauer A, Warnault P, Van Hijfte N, Borjini N, Chevé G, Yasri A.. (2016) Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors.. J Med Chem, 59 (8): (3886-3905). [PMID:27010810] [10.1021/acs.jmedchem.6b00087]
17. Zhu W, Chen H, Wang Y, Wang J, Peng X, Chen X, Gao Y, Li C, He Y, Ai J, Geng M, Zheng M, Liu H.. (2017) Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer.. J Med Chem, 60 (14): (6018-6035). [PMID:28714692] [10.1021/acs.jmedchem.7b00076]
18. Fukuda T, Goto R, Kiho T, Ueda K, Muramatsu S, Hashimoto M, Aki A, Watanabe K, Tanaka N.. (2017) Discovery of DS28120313 as a potent orally active hepcidin production inhibitor: Design and optimization of novel 4,6-disubstituted indazole derivatives.. Bioorg Med Chem Lett, 27 (23): (5252-5257). [PMID:29079471] [10.1016/j.bmcl.2017.10.031]
19. Myers SH, Temps C, Houston DR, Brunton VG, Unciti-Broceta A.. (2018) Development of Potent Inhibitors of Receptor Tyrosine Kinases by Ligand-Based Drug Design and Target-Biased Phenotypic Screening.. J Med Chem, 61 (5): (2104-2110). [PMID:29466002] [10.1021/acs.jmedchem.7b01605]
20. Baladi T, Aziz J, Dufour F, Abet V, Stoven V, Radvanyi F, Poyer F, Wu TD, Guerquin-Kern JL, Bernard-Pierrot I, Garrido SM, Piguel S.. (2018) Design, synthesis, biological evaluation and cellular imaging of imidazo[4,5-b]pyridine derivatives as potent and selective TAM inhibitors.. Bioorg Med Chem, 26 (20): (5510-5530). [PMID:30309671] [10.1016/j.bmc.2018.09.031]
21. Heng H, Wang Z, Li H, Huang Y, Lan Q, Guo X, Zhang L, Zhi Y, Cai J, Qin T, Xiang L, Wang S, Chen Y, Lu T, Lu S.. (2019) Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model.. Eur J Med Chem, 176 (248-267). [PMID:31103903] [10.1016/j.ejmech.2019.05.021]
22. Yuan T, Qi B, Jiang Z, Dong W, Zhong L, Bai L, Tong R, Yu J, Shi J.. (2019) Dual FLT3 inhibitors: Against the drug resistance of acute myeloid leukemia in recent decade.. Eur J Med Chem, 178 (468-483). [PMID:31207462] [10.1016/j.ejmech.2019.06.002]
23. Mathison CJN, Chianelli D, Rucker PV, Nelson J, Roland J, Huang Z, Yang Y, Jiang J, Xie YF, Epple R, Bursulaya B, Lee C, Gao MY, Shaffer J, Briones S, Sarkisova Y, Galkin A, Li L, Li N, Li C, Hua S, Kasibhatla S, Kinyamu-Akunda J, Kikkawa R, Molteni V, Tellew JE.. (2020) Efficacy and Tolerability of Pyrazolo[1,5-a]pyrimidine RET Kinase Inhibitors for the Treatment of Lung Adenocarcinoma.. ACS Med Chem Lett, 11 (4): (558-565). [PMID:32292564] [10.1021/acsmedchemlett.0c00015]
24. Nair S, Kumar SR, Paidi VR, Sistla R, Kantheti D, Polimera SR, Thangavel S, Mukherjee AJ, Das M, Bhide RS, Pitts WJ, Murugesan N, Dudhgoankar S, Nagar J, Subramani S, Mazumder D, Carman JA, Holloway DA, Li X, Fereshteh MP, Ruepp S, Palanisamy K, Mariappan TT, Maddi S, Saxena A, Elzinga P, Chimalakonda A, Ruan Q, Ghosh K, Bose S, Sack J, Yan C, Kiefer SE, Xie D, Newitt JA, Saravanakumar SP, Rampulla RA, Barrish JC, Carter PH, Hynes J.. (2020) Optimization of Nicotinamides as Potent and Selective IRAK4 Inhibitors with Efficacy in a Murine Model of Psoriasis.. ACS Med Chem Lett, 11 (7): (1402-1409). [PMID:32676146] [10.1021/acsmedchemlett.0c00082]
25. Mark, M R MR and 5 more authors.. (1994) rse, a novel receptor-type tyrosine kinase with homology to Axl/Ufo, is expressed at high levels in the brain.. The Journal of biological chemistry, (8): [PMID:7511603]
26. Toshima, J J, Ohashi, K K, Iwashita, S S and Mizuno, K K.. (1995) Autophosphorylation activity and association with Src family kinase of Sky receptor tyrosine kinase.. Biochemical and biophysical research communications, (17): [PMID:7537495]
27. Godowski, P J PJ and 5 more authors.. (1995) Reevaluation of the roles of protein S and Gas6 as ligands for the receptor tyrosine kinase Rse/Tyro 3.. Cell, (11): [PMID:7634325]
28. Crosier, K E KE and 6 more authors.. (1994) Isolation and characterization of the human DTK receptor tyrosine kinase.. Growth factors (Chur, Switzerland), [PMID:7857658]
29. Ohashi, K K, Mizuno, K K, Kuma, K K, Miyata, T T and Nakamura, T T.. (1994) Cloning of the cDNA for a novel receptor tyrosine kinase, Sky, predominantly expressed in brain.. Oncogene, [PMID:8108112]
30. Polvi, A A and 8 more authors.. (1993) The human TYRO3 gene and pseudogene are located in chromosome 15q14-q25.. Gene, (8): [PMID:8262388]
31. Kajii, Y Y and 8 more authors.. (1996) A tyrosine kinase-like molecule is localized in the nuclear membrane of neurons: hippocampal behavior under stress.. Biology of the cell, [PMID:9175267]
32. Hafizi, Sassan S and Dahlbäck, Björn B.. (2006) Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases.. Cytokine & growth factor reviews, [PMID:16737840]
33. Shimojima, Masayuki M and 8 more authors.. (2006) Tyro3 family-mediated cell entry of Ebola and Marburg viruses.. Journal of virology, [PMID:17005688]
34. Cosemans, J M E M JM and 10 more authors.. (2010) Potentiating role of Gas6 and Tyro3, Axl and Mer (TAM) receptors in human and murine platelet activation and thrombus stabilization.. Journal of thrombosis and haemostasis : JTH, [PMID:20546121]
35. Shimojima, Masayuki M, Ströher, Ute U, Ebihara, Hideki H, Feldmann, Heinz H and Kawaoka, Yoshihiro Y.. (2012) Identification of cell surface molecules involved in dystroglycan-independent Lassa virus cell entry.. Journal of virology, [PMID:22156524]
36. Shimojima, Masayuki and Kawaoka, Yoshihiro.. (2012) Cell surface molecules involved in infection mediated by lymphocytic choriomeningitis virus glycoprotein.. The Journal of veterinary medical science, [PMID:22673088]
37. Yin L, Li H, Liu W, Yao Z, Cheng Z, Zhang H, Zou H. (2018) A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy.. Eur J Med Chem, 144 (1-28). [PMID:29247857]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

浓度

体积

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

体积 1 (V1)

浓度 2 (C2)

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

质量（小瓶）

所需的复溶浓度